Advanced Renal Cell Carcinoma research hub
3 indexed studies · 0 currently recruiting
- authorisedPhase I and Phase II (Integrated)- Other
ROSETTA RCC-208: A Phase 1/2 Open-label, Multi-center, Randomized Study of Pumitamig Alone or in Combination with Ipilimumab or Cabozantinib in Participants with Advanced Renal Cell Carcinoma (RCC)
This study is testing an experimental medicine called pumitamig for adults with advanced kidney cancer. Doctors want to see how safe it is on its own or alongside other cancer drugs, and whether it can help shrink tumours or stop the cancer from getting worse.
Ireland · Romania · Italy - active not recruiting
Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment.
This study looks at how a treatment called cabozantinib, used alone or with another drug called nivolumab, works for people in the UK with advanced kidney cancer. Researchers want to see how patients use these drugs in normal clinic visits and understand any side effects.
Austria · Germany - active not recruitingPHASE1
A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma
This study looks at new drug combinations for advanced kidney cancer. We want to see how safe and effective MEDI5752 is when given with either Lenvatinib or Axitinib to people with this type of cancer.
United States · Australia · France